Table 2.
Specific absorbed dose estimates for critical organs under 177Lu-PSMA-617 or I&T therapy.
| Reference Study | Patient Number |
Molecule | Imaging Method |
Dose Convolution | Kidneys | Salivary Glands |
Lacrimal Glands | Bone Marrow | Liver | Spleen | Tumors |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Delker [28] | 5 | 617 | Whole body planar + SPECT-CT | MIRD * | 0.6 Gy/GBq |
1.4 Gy/GBq |
- | 0.012 Gy/GBq |
0.1 Gy/GBq |
0.1 Gy/GBq |
13.1 Gy/GBq |
| Hohberg [29] |
9 | 617 | Whole body planar | MIRD | 0.53 Gy/GBq |
0.72 Gy/GBq |
2.82 Gy/GBq |
- | - | - | - |
| Okamato [30] |
18 | I&T | Whole body planar | MIRD | 0.72 Gy/Gbq | 0.55–0.64 Gy/GBq |
3.8 Gy/GBq |
- | 0.12 Gy/GBq |
- | 3.2 Gy/GBq |
| Fendler [18] |
15 | 617 | SPECT | MIRD | 0.5–0.6 Gy/GBq |
1.0 Gy/GBq |
- | 0.002 Gy/Gbq |
0.1 Gy/Gbq |
0.1 Gy/Gbq |
6.1 Gy/GBq |
| Yadav [31] |
26 | 617 | Whole body planar | MIRD | 0.99 Gy/GBq |
1.24 Gy/GBq |
- | 0.048 Gy/GBq |
0.36 Gy/GBq |
- | 10.94 Gy/GBq |
| Violet [20] |
30 | 617 | SPECT-CT | Voxel based and MIRD | 0.39 Gy/GBq |
0.44–0.58 Gy/GBq |
- | 0.11 Gy/GBq |
0.1 Gy/GBq |
0.06 Gy/GBq |
11.5 Gy/GBq |
* MIRD: Model-based estimate of absorbed dose; SPECT, Single-photon emission computed tomography; -: not available.